Trial Information
Pilot Trial of Use of DMPA Injection and High Dose MPA Tablets in Outpatient
Inclusion Criteria:
- Women 18- 50
- Non-pregnant
- Candidate for outpatient management
- Able to understand and follow instructions
- Vital signs stable
- No severe anemia
- No medical conditions requiring transfusion
Exclusion Criteria:
- Pregnancy
- Breast cancer current or in last 5 years
- Allergy to MPA or DMPA
- Previous hormonal therapies
- Unstable vital signs
- Bleeding excessive enough to require surgical therapy or hospital admission
- Desire for pregnancy in next 6 months
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Slowing of acute bleeding.
Outcome Time Frame:
24-28 hours
Safety Issue:
Yes
Principal Investigator
Anita L. Nelson, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of California, Los Angeles
Authority:
United States: Institutional Review Board
Study ID:
13530-01
NCT ID:
NCT01148420
Start Date:
January 2009
Completion Date:
October 2010
Related Keywords:
- Dysfunctional Uterine Bleeding
- Hemorrhage
- Metrorrhagia
- Uterine Hemorrhage
Name | Location |
Harbor-UCLA Urgent Care |
Torrance, California 90502 |